

Statement of unaudited financial results for the quarter ended 30 June 2018

SI No.	Particulars	Rs in lakhs except for earnings per share data			
		3 months ended 30/06/2018 (Unaudited)	3 months ended 31/03/2018 (Audited) Refer Note 7	3 months ended 30/06/2017 (Unaudited)	Year ended 31/03/2018 (Audited)
1	Revenue				
	a) Revenue from operations	16,143.68	15,072.66	12,846.58	57,198.92
	b) Other income (Refer Note 5)	342.28	233.82	465.41	1,224.76
	Total revenue	16,485.96	15,306.48	13,311.99	58,423.68
2	Expenses				
	(a) Cost of materials consumed	1,687.33	1,149.07	547.77	2,788.01
	(b) Purchase of stock-in-trade	1,999.45	2,472.62	5,843.96	20,421.17
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,648.04	783.69	(1,877.19)	(5,099.57)
	(d) Excise duty	-	-	98.50	98.50
	(e) Employee benefits expense	4,307.28	4,507.37	3,493.88	15,353.09
	(f) Depreciation and amortisation expense	355.04	355.08	370.80	1,473.75
	(g) Selling, marketing and distribution expense	2,862.02	2,111.30	1,185.91	7,280.51
	(h) Other expenses	2,711.61	2,521.67	2,932.06	11,728.21
	(i) Finance cost	-	-	-	-
	Total expenses	15,570.77	13,900.80	12,595.69	54,043.67
3	Profit before exceptional and extraordinary items and tax (1-2)	915.19	1,405.68	716.30	4,380.01
4	Exceptional items	-	-	-	-
5	Profit before extraordinary items and tax (3+4)	915.19	1,405.68	716.30	4,380.01
6	Extraordinary items	-	-	-	-
7	Profit before tax (5+6)	915.19	1,405.68	716.30	4,380.01
8	Tax expense				
	- Current tax	263.47	194.75	152.60	899.74
	- Deferred tax	12.38	888.79	(16.03)	888.79
	Total tax expense	275.85	1,083.54	136.57	1,788.53
9	Profit for the period (7-8)	639.34	322.14	579.73	2,591.48
10	Other comprehensive income, net of income tax				
	A. Items that will not be reclassified to profit or loss	166.51	(510.59)	62.36	(227.99)
	B. Items that will be reclassified to profit or loss	-	-	-	-
	Total other comprehensive income, net of income tax	166.51	(510.59)	62.36	(227.99)
	Total comprehensive income for the period (9+10)	805.85	(188.45)	642.09	2,363.49
11	Paid-up equity share capital (Face value of Rs 2/- per equity share)	500.00	500.00	500.00	500.00
12	Earnings per equity share of Rs 2/- each (basic and diluted)	2.56	1.29	2.32	10.37

Jagan



AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Statement of unaudited financial results for the quarter ended 30 June 2018

Notes:

- 1 The above statement of results has been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 13 August 2018. The statutory auditors of the Company have carried out a limited review of this statement of results for the quarter ended 30 June 2018.
- 2 This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3 Ind AS 115 'Revenue from contracts with customers' mandatory for reporting periods beginning on or after 1 April 2018, replaces existing revenue recognition requirements. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 1 April 2018. The adoption of the standard did not have any impact on the financial results for the quarter.
- 4 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 5 Other Income includes interest on income tax refund of Rs. 101.92 lakhs (3 months ended 30 June 2017: Rs. 268.26 lakhs).
- 6 As previously disclosed, by way a of letter dated 1 March 2014, AstraZeneca Pharmaceuticals AB, the promoter of the Company had proposed a voluntary delisting of the Company's equity shares from the National Stock Exchange and the Bombay Stock Exchange. Such proposed delisting is subject to an on-going inquiry with SEBI and that inquiry has not yet been resolved. In any event, based on the passage of time, any potential future proposal for voluntary delisting of the Company would need to be conducted de novo.
- 7 Figures for the quarter ended 31 March 2018 are the balancing figures between audited figures in respect of the full financial year ended 31 March 2018 and the published year to date figures up to the third quarter of the relevant financial year i.e 31 December 2017, which were subjected to review.
- 8 Previous period's figures have been regrouped, where necessary, to conform with the current period's presentation for the purpose of comparability.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Place: Bengaluru
Date: 13 August 2018




Gagan Singh Bedi
Managing Director